163 related articles for article (PubMed ID: 23276590)
1. Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal.
Teo M; Downey FP; McDermott RS
Clin Genitourin Cancer; 2013 Jun; 11(2):198-200. PubMed ID: 23276590
[No Abstract] [Full Text] [Related]
2. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
Gyawali B; Ando Y
Ann Oncol; 2017 Apr; 28(4):898-899. PubMed ID: 27993814
[No Abstract] [Full Text] [Related]
4. 'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer.
Rothermundt CA; Omlin A; Gillessen S
Ann Oncol; 2009 Jun; 20(6):1144-6. PubMed ID: 19465428
[No Abstract] [Full Text] [Related]
5. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
[TBL] [Abstract][Full Text] [Related]
6. Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.
Vaz MA; Pachón V; Grande E; Ferreiro R; Carrato A
Anticancer Drugs; 2011 Sep; 22(8):817-21. PubMed ID: 21566523
[TBL] [Abstract][Full Text] [Related]
7. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Nicholaou T; Wong R; Davis ID
Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
[No Abstract] [Full Text] [Related]
8. Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma.
Van Keerberghen CA; Jean-Baptiste J; Wolter P; Zucman-Rossi J; Schöffski P; Beuselinck B
Clin Genitourin Cancer; 2015 Dec; 13(6):e407-10. PubMed ID: 26026260
[No Abstract] [Full Text] [Related]
9. Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.
Daste A; Gross-Goupil M; Quivy A; François L; Bernhard JC; Ravaud A
Clin Genitourin Cancer; 2016 Oct; 14(5):e525-e527. PubMed ID: 27185091
[No Abstract] [Full Text] [Related]
10. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
[No Abstract] [Full Text] [Related]
11. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.
Thibault F; Billemont B; Rixe O
J Neurooncol; 2008 Jan; 86(2):243-4. PubMed ID: 17634858
[No Abstract] [Full Text] [Related]
12. Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor?
Gambini D; Locatelli E; Gianelli U; Bareggi C; Galassi B; Visintin R; Massironi S; Dell'orto PG; Tomirotti M
Anticancer Res; 2014 Dec; 34(12):7361-5. PubMed ID: 25503173
[TBL] [Abstract][Full Text] [Related]
13. Long-term response with sunitinib for metastatic renal cell carcinoma.
Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
[TBL] [Abstract][Full Text] [Related]
14. [Use of sunitinib in metastatic renal cell carcinoma patients with poor prognosis].
Timofeev IV; Demidov LV; Petenko NN
Vopr Onkol; 2011; 57(1):50-4. PubMed ID: 21598708
[TBL] [Abstract][Full Text] [Related]
15. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
Bex A; Van der Veldt AA; Blank C; Meijerink MR; Boven E; Haanen JB
Acta Oncol; 2010 May; 49(4):520-3. PubMed ID: 20105087
[No Abstract] [Full Text] [Related]
16. Dramatic effect of sunitinib with rapid but transient improvement for psoriasis in a patient with metastatic renal carcinoma.
Kato Y; Yamamoto T
J Dermatol; 2013 Dec; 40(12):1069-70. PubMed ID: 24330182
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
Purmonen TT
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):383-93. PubMed ID: 21831017
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in renal-cell carcinoma: expanded indications.
Choueiri TK; Bellmunt J
Lancet Oncol; 2009 Aug; 10(8):740. PubMed ID: 19615941
[No Abstract] [Full Text] [Related]
19. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
20. Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
Park I; Park K; Park S; Ahn Y; Ahn JH; Choi HJ; Jeong IG; Song C; Hong JH; Kim CS; Ahn H; Lee JL
Clin Genitourin Cancer; 2013 Sep; 11(3):276-82. PubMed ID: 23332873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
